What IHAS does

iHAS is a privately-held Bulgarian healthcare services company founded in 2012 and headquartered in Sofia (15a Krum Kyulyavkov Str., 1172 Sofia). It operates a dual-line business: (1) exclusive Bulgarian distribution of the Oncotype DX genomic diagnostic test portfolio under representation agreements with Genomic Health Inc. and Exact Sciences Inc., and (2) facilitation of outbound medical tourism for Bulgarian patients to Switzerland's Hirslanden Hospital Group. The company serves Bulgarian cancer patients — primarily newly diagnosed with breast, colon, or prostate cancer — and the prescribing oncologists, surgeons, and medical geneticists who use test results to inform chemotherapy and recurrence-risk decisions. Secondary customers include Bulgarian patients seeking second opinions or treatment abroad through iHAS-organized consultations, hospital admissions, and travel logistics.

The core product distributed is Oncotype DX — a multi-gene expression assay platform that analyzes tumor tissue (21 genes for breast cancer, 12 for colon cancer, plus prostate and DCIS variants) and outputs a Recurrence Score (0–100) predicting ten-year recurrence risk and the likelihood of chemotherapy benefit. iHAS does not own or develop this technology; it operates as the order-and-results intermediary for Bulgaria. The medical-tourism offering layers remote document review, second-opinion consultations with international experts, hospital placement at Hirslanden's 14 Swiss facilities (concentrated in Zurich and Bern), airport transfers, accommodation, translation, and cultural programming. A web-based patient registry and social network is offered as an adjunct service.

iHAS generates revenue through two streams: one-time per-test fees on Oncotype DX orders (pricing is quote-based and not covered by Bulgaria's National Health Insurance Fund, requiring patient or institutional out-of-pocket payment) and professional-service fees for medical-tourism facilitation. The go-to-market is sales-led and direct, relying on physician referrals, the company's website, and inbound phone/email contact rather than digital marketing infrastructure. The company has no disclosed funding rounds, no headcount data, and no institutional ownership signals; it appears founder-controlled with a single named founder (George Pishtiyski) and a clinical consultant (Dr. Ivanka Dimova).

Name

IHAS

Legal name

iHAS Ltd (ИХАС ЕООД)

Website

https://ihas.eu

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

iHAS is a Bulgarian healthcare services company that distributes Oncotype DX genomic cancer diagnostic tests in Bulgaria as the exclusive representative of Genomic Health and Exact Sciences, and facilitates medical tourism to Switzerland's Hirslanden Hospital Group for Bulgarian patients.

Ownership category

akta.pro rank

Product category

Cancer Diagnostics & Medical Tourism Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)

akta.pro secondary industries

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Reference & Esoteric Testing Laboratories (HLAFAMAJ)

Keywords

• Genomic diagnostic tests
• Medical tourism services
• Cancer diagnostics distribution
• Personalized oncology treatment
• Healthcare facilitation services

Headquarters

HQ city

Sofia

HQ country

Bulgaria

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Genetic Analysis Assays: Sale of Oncotype DX diagnostic tests for breast, colon, and prostate cancer. These are one-time tests performed on tumor tissue samples to provide genomic information for treatment decisions.
2. Medical Tourism Services: Facilitation services for Bulgarian patients seeking medical treatment abroad, including organizing remote and face-to-face consultations with international experts, arranging treatment at Hirslanden hospitals in Switzerland, providing airport transfers, accommodation, translation services, and cultural programs.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

IHAS distributes Oncotype DX genomic diagnostic tests for breast, colon, prostate, and DCIS cancer in Bulgaria as the exclusive local representative of Genomic Health Inc. and Exact Sciences Inc., enabling personalized cancer treatment decisions through multi-gene tumor analysis. The company additionally provides medical tourism facilitation services connecting Bulgarian patients with international healthcare providers, notably the Hirslanden hospital group in Switzerland.

Product overview

iHAS is a Bulgarian healthcare services company offering a portfolio of genomic diagnostic tests and medical tourism services. The core products are Oncotype DX tests (for breast cancer, colon cancer, prostate cancer, and DCIS) distributed in Bulgaria in partnership with Genomic Health Inc. and Exact Sciences Inc. These genomic assays analyze tumor tissue to provide personalized recurrence risk scores and treatment recommendations. Additionally, iHAS provides medical tourism services facilitating access to Swiss hospitals (Hirslanden Group) and international medical experts. The company also offers a web-based patient registry/social network for patients with specific conditions.

Differentiator

Problem solved

Functional benefit

Products and services

• Oncotype DX Breast Cancer Assay Genomic diagnostic test for early-stage, estrogen receptor-positive (ER+) breast cancer that analyzes 21 genes in tumor tissue to provide a Recurrence Score (0-100), predicting 10-year recurrence risk and likelihood of chemotherapy benefit for patients.
• Oncotype DX Colon Cancer Assay First commercial genomic diagnostic test evaluating expression levels of 12 genes in tumor samples to assess recurrence risk in Stage II colon cancer patients, supporting individualized treatment decisions.
• Oncotype DX Prostate Cancer Assay Genomic test developed to help men with newly diagnosed, early-stage prostate cancer select appropriate treatment by determining cancer risk before treatment begins, using a proprietary analysis platform for formalin-fixed paraffin-embedded prostate tissue.
• Oncotype DX DCIS Test

Quantifiable outcome

• 37% of patients had their treatment decision changed based on Recurrence Score results
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core.

• Genomic Health, Inc.coreChannel Partner/ Reseller/ DistributoriHAS Ltd is the exclusive representative of Genomic Health Inc. and Exact Sciences Inc. for Bulgaria. Genomic Health is a global medical company (NASDAQ: GHDX) that provides actionable genomic information to personalize treatment decisions. Their Oncotype DX tests for breast, colon, and prostate cancer are clinically validated and included in major international treatment guidelines.
• Hirslanden Hospital GroupcoreStrategic or Co-development PartneriHAS works with Hirslanden hospital group, one of Switzerland's leading private hospital groups with 14 first-class hospitals. The partnership focuses on clinics in Zurich (Klinik Hirslanden, Klinik im Park) and Bern (Klinik Beau-Site, Klinik Permanence, Salem Hospital). iHAS acts as a connecting link between foreign patients and Swiss hospitals, guaranteeing optimal and fast solutions for medical problems.
• Exact Sciences Inc.coreChannel Partner/ Reseller/ DistributoriHAS Ltd is the exclusive representative of Exact Sciences Inc. for Bulgaria alongside Genomic Health Inc. Exact Sciences develops and provides diagnostic tests for cancer treatment decisions.

Scale indicators4 records

Recent moves5 records

Expansion highlights3 records

Broad incumbents

• SYNLAB: Europe's largest medical diagnostics services provider, offering routine and esoteric/molecular testing including oncology across the continent. Relevant incumbent peer because it competes for the same Bulgarian and CEE physician demand for advanced oncology diagnostics that iHAS distributes.
• Sonic Healthcare: Global diagnostics provider with extensive European laboratory operations offering specialty and molecular testing. Comparable to iHAS as a broad incumbent that ultimately delivers many of the same advanced oncology assays iHAS helps distribute in Bulgaria.
• Exact Sciences: Owner of the Oncotype DX franchise that iHAS exclusively distributes in Bulgaria. Comparable as the upstream developer of the core product iHAS sells and as the principal whose strategic decisions (pricing, exclusivity, direct entry) materially affect iHAS' economics.
• Unilabs: European clinical laboratory and diagnostics network with strong presence in molecular and specialty testing. Comparable to iHAS in that it provides the underlying molecular diagnostic infrastructure (including oncology testing) that iHAS effectively distributes in Bulgaria.

Direct peers

• Booking Health: Medical tourism facilitator that arranges treatment abroad (notably in Germany, Switzerland and Israel) for patients from Eastern Europe and the CIS. Closely comparable to iHAS' Hirslanden medical tourism line in target customer (CEE patients seeking Western European care) and service scope.
• Medicover: Sweden-based healthcare group operating diagnostics, specialty care and hospitals across Central and Eastern Europe including Bulgaria. Most directly comparable peer to iHAS because it combines clinical laboratory/diagnostic services with broader healthcare delivery in the same CEE geography iHAS serves.

Emerging players

• Medigo: Global platform that connects patients with international clinics and facilitates cross-border medical travel. Comparable to iHAS' medical tourism arm in bundling provider selection, logistics and treatment coordination for outbound patients.

Regional players

• Wiener Privatklinik: Austrian private hospital group with a dedicated international patient office catering to CEE and CIS patients seeking advanced Western European care. Comparable to iHAS' medical tourism model in geography and patient origin.
• Docrates Cancer Center: Privately owned Finnish specialty cancer hospital serving international patients from across Europe and Russia. Comparable to the Hirslanden-side of iHAS' offering as a destination for personalized cancer diagnostics and treatment for cross-border patients.
• Genolier Swiss Medical Network: Swiss private hospital network competing with Hirslanden for international and CEE medical tourism patients. Comparable as an alternative Swiss destination that Bulgarian patients could be channeled to, similar to how iHAS works with Hirslanden today.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/ihas

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IHAS